Recent reports that two plasma donors in Winnipeg died following donations to for-profit plasma collection centres have reignited debate about the role of paid plasma collection in Canada. While the circumstances remain under investigation, the provincial health ministry is reportedly considering whether to ban paid plasma donation. These developments raise urgent questions about how Canada regulates an industry that relies on the biological contributions of its donors.

Canada’s growing plasma industry promises life-saving therapies for thousands of patients. Plasma-derived medicines are essential treatments for individuals living with immune disorders, hemophilia and other serious conditions. As global demand for these therapies continues to rise, governments are seeking ways to expand plasma collection. In Canada, this has included compensation for donors.

Over the past decade, debates about the commercialization of plasma collection have intensified across the country. In 2016, discussions escalated when private plasma collection companies began opening sites in provinces such as Saskatchewan. Supporters argue that compensating donors will increase Canada’s domestic plasma supply and reduce reliance on international imports. Given rising demand for plasma-derived therapies, strengthening Canada’s supply chain is an understandable goal.

Yet the expansion of private plasma collection raises difficult ethical questions about equity, exploitation and the broader social costs of a market-driven plasma economy. This tension reflects a broader policy dilemma: how to expand plasma supply without shifting the burden of that expansion onto those who are already economically vulnerable.

Evidence from countries where paid plasma donation is well established suggests that collection centres often concentrate in economically disadvantaged communities. In the United States, plasma donation has become a source of income for individuals facing financial insecurity, particularly in low-income neighbourhoods. While plasma-derived therapies generate billions in global pharmaceutical revenue, the individuals supplying this resource often receive relatively small payments in return.

These patterns reflect broader structural dynamics. Scholars have described them as a form of “biological labour,” in which people exchange bodily materials such as plasma, eggs or stem cells for financial compensation. Historically, marginalized populations have disproportionately borne the burdens of biomedical extraction while wealthier populations benefit from the resulting medical innovations.

Canada is not immune to these dynamics. Social determinants of health including income inequality, employment precarity and systemic discrimination, shape who may be most likely to participate in compensated plasma donation programs. Racialized communities, including Black Canadians, already face disproportionate barriers to economic stability and health-care access. Without careful oversight, the commercialization could deepen these inequities rather than address them.

The problem is not simply the existence of compensation for plasma donation. The issue is the absence of safeguards to ensure that plasma collection systems operate in ways that are fair, transparent and socially responsible. Canada’s regulatory framework focuses primarily on the safety and quality of blood and plasma products. Health Canada’s Blood Regulations ensure that plasma therapies meet strict safety standards and govern the collection and distribution of blood products. Public agencies such as Canadian Blood Services continue to promote voluntary and unpaid donation in line with World Health Organization recommendations.

However, existing regulations do little to examine the broader equity implications of plasma commercialization, leaving critical questions unanswered about who is most likely to participate in plasma donation, where collection centres are located and who ultimately benefits. These are questions that risk being overshadowed by market incentives without an equity-focused policy lens.

Canada still has an opportunity to address these gaps as the plasma industry expands. One step forward would be a National Ethical Plasma Governance Framework that embeds equity into the oversight of plasma collection, ensuring that regulations address not only safety, but also the social and economic conditions under which plasma is collected

This could include requiring plasma collection companies to conduct equity impact assessments as part of licensing process, evaluating outreach practices, compensation models and donor demographics to ensure economically vulnerable communities are not disproportionately represented among donors.

Community oversight mechanisms could strengthen accountability and rebuild public trust, particularly in communities historically excluded from or harmed by donation systems. A national advisory council of patient advocates, public-health experts and community organizations could help monitor plasma collection practices, provide input on outreach and engagement and ensure affected communities have a meaningful role in decision-making. Policymakers could also consider ways to ensure that the benefits of plasma collection are shared more equitably, particularly in areas where collection centres are located.

Importantly, these measures would not prevent Canada from expanding its plasma supply, but would help ensure that expansion occurs within a framework that prioritizes ethical governance and public-health equity.

Plasma therapies save lives and are essential for many patients. But the systems that produce them must also reflect the values of fairness, dignity and social responsibility. The question is not simply how to increase plasma supply, but whether we are willing to do so in a way that protects both public health and social justice.

This article was originally published on March 31, 2026 in https://www.healthing.ca/